NCCN Guidelines® Insights - Breast Cancer, Version 3.2018

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

Target Audience

This activity is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to NCCN Guidelines for Breast Cancer.
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Breast Cancer.
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca, Celgene Corporation, Clovis Oncology, Eisai, Genentech, Genomic Health, Inc., Novartis, Taiho Oncology, Inc., and TESARO. This activity is supported by an independent educational grant from AbbVie. This activity is supported by educational funding provided by Amgen. This activity is supported by an unrestricted educational grant from Gilead Sciences, Medical Affairs.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
02/10/2019
Course expires: 
02/10/2020
Cost:
$0.00

NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). 

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.

Definitions  
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. 

Faculty Disclaimers  
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.

The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.

Individuals Who Provided Content Development and/or Authorship Assistance:
Matthew P. Goetz, MD, Panel Member, has disclosed that he has served as a scientific advisor for Biotheranostics, Eli Lilly and Company, and Sermonix Pharmaceuticals; has received grant/research support from Eli Lilly and Company and Pfizer Inc.; and has received consulting fees/honoraria from Genomic Health, Inc., Biovica International AB, and Sermonix Pharmaceuticals.
William J. Gradishar, MD, Panel Chair, has disclosed that he has no relevant financial relationships.
Jame Abraham, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Harold J. Burstein, MD, PhD, Panel Member, has disclosed that he has no relevant financial relationships.
Chau Dang, MD, Panel Member, has disclosed that she has received grant/research support from Roche/Genentech and Puma Biotechnology, Inc.
Lori J. Goldstein, MD, Panel Member, has disclosed that she has served as a scientific advisor for Amgen Inc., AstraZeneca Pharmaceuticals LP, Daiichi Sankyo, Inc., Eisai Inc., Genomic Health, Inc., and Merck & Co., Inc.
Steven J. Isakoff, MD, PhD, Panel Member, has disclosed that he receives grant/research support from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Genentech, Inc., Merck & Co., Inc., OncoPep, Inc., and PharmaMar. He also has received consulting fees/honoraria from Genentech, Inc., Immunomedics, Inc., Myriad Genetic Laboratories, Inc., Hengrui Therapeutics, Inc., Mylan, and Puma Biotechnology, Inc.
Meena S. Moran, MD, Panel Member, has disclosed that she has no relevant financial relationships.
Hope S. Rugo, MD, Panel Member, has disclosed that she receives grant/research support from Pfizer Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals; Eli Lilly and Company; OBI Pharma; Genentech, Inc.; Odonate Therapeutics, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; Seattle Genetics, Inc.; and MacroGenics, Inc. She also receives consulting fees/honoraria from Eli Lilly and Company, Mylan, Pfizer Inc., Amgen Inc., Merck & Co., Inc., and Puma Biotechnology, Inc.
Karen Lisa Smith, MD, MPH, Panel Member, has disclosed that she has received grant/research support from Pfizer Inc. and Puma Biotechnology, Inc., and that her spouse has equity interest/stock options in AbbVie Inc. and Abbott Laboratories.
Hatem Soliman, MD, Panel Member, has disclosed that he has served as a consultant for Eli Lilly and Company, Pfizer Inc., AstraZeneca Pharmaceuticals LP, Novartis AG, Puma Biotechnology, Inc., and Celgene Corporation.
Melinda L. Telli, MD, Panel Member, has disclosed that she has served as a scientific advisor for Celldex Therapeutics; Genentech, Inc.; Immunomedics, Inc.; Merck & Co., Inc.; Aduro BioTech, Inc.; Pfizer Inc.; and Tesaro, Inc.
John H. Ward, MD, Panel Member, has disclosed that he has no relevant financial relationships.
Dorothy A. Shead, MS, Director, Patient Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. 

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: 0836-0000-19-010-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until February 10, 2020. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Accreditation Period

Course opens: 
02/10/2019
Course expires: 
02/10/2020

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing